-
公开(公告)号：KR20180021740A
公开(公告)日：2018-03-05
申请号：KR20177037849
申请日：2016-06-02
Applicant: PHARMACYCLICS LLC
Inventor： ATALLAH GORDANA BABIC , CHEN WEI , JIA ZHAOZHONG J , POZZAN ALFONSO , RAVEGLIA LUCAL FRANCESCO , ZANALETTI RICCARDO
IPC: C07D417/14 , A61K31/497 , A61K31/53 , A61P19/02 , A61P19/10 , A61P35/00 , C07D401/14
CPC classification number: C07D417/14 , C07D401/04 , C07D401/14 , C07D405/14 , C07D409/14 , C07D413/14 , C07D471/04 , C07D471/08
Abstract: 브루톤티로신키나제 (Btk)의가역적및 비가역적억제제가본 명세서에서개시된다. 상기화합물을포함하는약제학적조성물이또한개시된다. 상기 Btk 억제제를사용하는방법은자가면역질환또는병태, 이종면역질환또는병태, 림프종을포함하는암, 및염증성질환또는병태의치료를위해, 단독으로또는다른치료제와함께기재된다.
Abstract translation: 说明书中公开了bruton酪氨酸激酶（Btk）的可逆和不可逆抑制剂。 还公开了包含这些化合物的药物组合物。 描述了单独或与其他治疗剂组合用于治疗自身免疫疾病或病症，异源免疫疾病或病症，包括淋巴瘤的癌症和炎性疾病或病症的Btk抑制剂的使用方法。
-
Patent Agency Ranking
公开(公告)号：WO2016196776A3
公开(公告)日：2017-01-05
申请号：PCT/US2016035489
申请日：2016-06-02
Applicant: PHARMACYCLICS LLC
Inventor： ATALLAH GORDANA BABIC , CHEN WEI , JIA ZHAOZHONG J , POZZAN ALFONSO , RAVEGLIA LUCAL FRANCESCO , ZANALETTI RICCARDO
IPC: C07D403/12 , A61K31/497 , A61K31/53
CPC classification number: C07D417/14 , C07D401/04 , C07D401/14 , C07D405/14 , C07D409/14 , C07D413/14 , C07D471/04 , C07D471/08
Abstract: Disclosed herein are reversible and irreversible inhibitors of Bruton's tyrosine kinase (Btk). Also disclosed are pharmaceutical compositions that include the compounds. Methods of using the Btk inhibitors are describeded, alone or in combination with other therapeutic agents, for the treatment of autoimmune diseases or conditions, heteroimmune diseases or conditions, cancer, including lymphoma, and inflammatory diseases or conditions.
Abstract translation: 本文公开了可逆和不可逆的Bruton酪氨酸激酶（Btk）抑制剂。 还公开了包含化合物的药物组合物。 描述了使用Btk抑制剂单独或与其它治疗剂组合用于治疗自身免疫疾病或病症，异种免疫疾病或病症，癌症，包括淋巴瘤和炎性疾病或病症的方法。
-
公开(公告)号：MA42623A
公开(公告)日：2018-06-20
申请号：MA42623
申请日：2016-06-02
Applicant: PHARMACYCLICS LLC
Inventor： ATALLAH GORDANA BABIC , CHEN WEI , JIA ZHAOZHONG J , POZZAN ALFONSO , RAVEGLIA LUCAL FRANCESCO , ZANALETTI RICCARDO
IPC: A61K31/497 , A61K31/53 , C07D403/12
-
公开(公告)号：AU2016270907B2
公开(公告)日：2020-09-17
申请号：AU2016270907
申请日：2016-06-02
Applicant: PHARMACYCLICS LLC
Inventor： ATALLAH GORDANA BABIC , CHEN WEI , JIA ZHAOZHONG J , POZZAN ALFONSO , RAVEGLIA LUCAL FRANCESCO , ZANALETTI RICCARDO
IPC: C07D403/12 , A61K31/497 , A61K31/53 , A61K31/55 , C07D417/14
Abstract: Disclosed herein are reversible and irreversible inhibitors of Bruton's tyrosine kinase (Btk). Also disclosed are pharmaceutical compositions that include the compounds. Methods of using the Btk inhibitors are describeded, alone or in combination with other therapeutic agents, for the treatment of autoimmune diseases or conditions, heteroimmune diseases or conditions, cancer, including lymphoma, and inflammatory diseases or conditions.
-
公开(公告)号：AU2016270907A1
公开(公告)日：2017-12-07
申请号：AU2016270907
申请日：2016-06-02
Applicant: PHARMACYCLICS LLC
Inventor： ATALLAH GORDANA BABIC , CHEN WEI , JIA ZHAOZHONG J , POZZAN ALFONSO , RAVEGLIA LUCAL FRANCESCO , ZANALETTI RICCARDO
IPC: C07D403/12 , A61K31/497 , A61K31/53 , A61K31/55 , C07D417/14
Abstract: Disclosed herein are reversible and irreversible inhibitors of Bruton's tyrosine kinase (Btk). Also disclosed are pharmaceutical compositions that include the compounds. Methods of using the Btk inhibitors are describeded, alone or in combination with other therapeutic agents, for the treatment of autoimmune diseases or conditions, heteroimmune diseases or conditions, cancer, including lymphoma, and inflammatory diseases or conditions.
-
公开(公告)号：CA2987054A1
公开(公告)日：2016-12-08
申请号：CA2987054
申请日：2016-06-02
Applicant: PHARMACYCLICS LLC
Inventor： ATALLAH GORDANA BABIC , CHEN WEI , JIA ZHAOZHONG J , POZZAN ALFONSO , RAVEGLIA LUCAL FRANCESCO , ZANALETTI RICCARDO
IPC: C07D403/12 , A61K31/497 , A61K31/53 , C07D417/14
Abstract: Disclosed herein are reversible and irreversible inhibitors of Bruton's tyrosine kinase (Btk). Also disclosed are pharmaceutical compositions that include the compounds. Methods of using the Btk inhibitors are describeded, alone or in combination with other therapeutic agents, for the treatment of autoimmune diseases or conditions, heteroimmune diseases or conditions, cancer, including lymphoma, and inflammatory diseases or conditions.
-
-
-
-
-
Search Results
6
records
(took 0.032 seconds)
